Thanks for your prompt response,
@otherperspective.
Good to know I am not imagining a misprice by analysts of 100% for their pricing models, not to mention the other goodies/off label marketing drive clearly spelt out today.
Agree that the embarrassing and really just gutless local biotech analyst coverage for mesoblast is a blight on the Australian sector. Whilst they have been recommending speccy rubbish (too many to name) over the last 2 years for their clients (most likely due to paid or CR fee incentivization), they did not have the fortitude to name MSB as a screaming speccy in March 2024 and now as investment grade BUY with commercial revenues incoming and reference pricing established.
The final embarrassment is the meagre 10% pop in SP from the local investor community on a fundamental DCF rerate based on reference pricing announced today. Last time I checked, a upside surprise of 100% on expected revenue for a new product made a little more impact than 10% on the SP, especially from an oversold condition. But there you go, I'm just a dumb retail investor trying to buy in at inflection points. I'll continue to back what is logical and hope the logic catches on in the markets, like it did after March 2024.
(20min delay)